Immune-related vitiligo-like-depigmentation

Clinical trials for Immune-related vitiligo-like-depigmentation explained in plain language.

Never miss a new study

Get alerted when new Immune-related vitiligo-like-depigmentation trials appear

Sign up with your email to follow new studies for Immune-related vitiligo-like-depigmentation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?

Disease control Ongoing

This study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how m…

Matched conditions: IMMUNE-RELATED VITILIGO-LIKE-DEPIGMENTATION

Phase 2 • Sponsor: University of Zurich • Aim: Disease control

Last updated Jul 26, 2026 00:00 UTC

Immune-related vitiligo-like-depigmentation

Get alerted when new Immune-related vitiligo-like-depigmentation trials appear

Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?